Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049 · Anthos Therapeutics, Inc. · PHASE3 · terminated · last registry update 2026-02-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, Anthos Therapeutics, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F11 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-17Results posted on the registry: Pharvaris Netherlands B.V., Deucrictibant low dose + Deucrictibant high dose (NCT05047185)
- 2026-08-17Also stopped (terminated): Pharvaris Netherlands B.V., Deucrictibant low dose + Deucrictibant high dose (NCT05047185)
- 2026-07-31Phase 3 first posted: Novartis Pharmaceuticals, Abelacimab (NCT07739888)
- 2026-05-08Results posted on the registry: Ionis Pharmaceuticals, Inc., Donidalorsen (NCT04307381)
- 2026-04-17Also stopped (terminated): Anthos Therapeutics, Inc., Abelacimab + Dalteparin (NCT05171075)
- 2025-12-17Results posted on the registry: Pharvaris Netherlands B.V., Deucrictibant + Placebo (NCT04618211)
- 2025-12-05Phase 3 first posted: Pharvaris Netherlands B.V., Deucrictibant + Placebo (NCT07266805)
- 2025-07-30Results posted on the registry: Anthos Therapeutics, Inc., Abelacimab + Rivaroxaban (NCT04755283)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision